These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 11957763)

  • 21. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of treating lower urinary tract symptoms on health-related quality of life: a short-term outcome.
    Quek KF; Loh CS; Low WY; Razack AH; Chua CB
    Singapore Med J; 2002 Aug; 43(8):391-8. PubMed ID: 12507023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study.
    Zhang K; Yu W; Jin J; Ye H; Wang X; Zhang N; Yang Y; Zhong C; Wan B
    Urology; 2011 Sep; 78(3):636-40. PubMed ID: 21696807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies.
    Robertson C; Link CL; Onel E; Mazzetta C; Keech M; Hobbs R; Fourcade R; Kiemeney L; Lee C; Boyle P; McKinlay JB
    BJU Int; 2007 Feb; 99(2):347-54. PubMed ID: 17313423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study.
    Komiya A; Suzuki H; Awa Y; Egoshi K; Onishi T; Nakatsu H; Ohki T; Mikami K; Sato N; Araki K; Ota S; Naya Y; Ichikawa T
    Int J Urol; 2010 Jun; 17(6):555-62. PubMed ID: 20370847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation.
    Nickel JC; Elhilali M; Emberton M; Vallancien G;
    BJU Int; 2006 Jun; 97(6):1242-6. PubMed ID: 16686719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of orally disintegrating tamsulosin tablets in Taiwanese patients with benign prostatic hyperplasia.
    Lin KH; Lin YW; Wen YC; Lee LM
    Aging Male; 2012 Dec; 15(4):246-52. PubMed ID: 23067262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
    Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
    Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
    Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting.
    Flannery MT; Ramsdell J; Ranhosky A; Davidai G; Ruoff G
    Curr Med Res Opin; 2006 Apr; 22(4):721-30. PubMed ID: 16684433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride.
    Zlotta AR; Teillac P; Raynaud JP; Schulman CC
    Eur Urol; 2005 Aug; 48(2):269-76. PubMed ID: 15939527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study.
    Chung MS; Lee SH; Park KK; Yoo SJ; Chung BH
    Int J Clin Pract; 2011 Nov; 65(11):1193-9. PubMed ID: 21995695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia.
    Michel MC; Mehlburger L; Schumacher H; Bressel HU; Goepel M
    J Urol; 2000 Jun; 163(6):1725-9. PubMed ID: 10799169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group.
    Chapple CR; Baert L; Thind P; Höfner K; Khoe GS; Spångberg A
    Eur Urol; 1997; 32(4):462-70. PubMed ID: 9412807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.
    van Moorselaar RJ; Hartung R; Emberton M; Harving N; Matzkin H; Elhilali M; Alcaraz A; Vallancien G;
    BJU Int; 2005 Mar; 95(4):603-8. PubMed ID: 15705088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.
    Xue Z; Zhang Y; Ding Q; He Z; Wang J; Xu K
    Int J Urol; 2007 Feb; 14(2):118-22. PubMed ID: 17302567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia.
    Schulman CC; Lock TM; Buzelin JM; Boeminghaus F; Stephenson TP; Talja M;
    J Urol; 2001 Oct; 166(4):1358-63. PubMed ID: 11547074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.